Association of heartbeat complexity with survival in advanced non-small cell lung cancer patients

被引:1
|
作者
Wu, Shuang [1 ,2 ]
Li, Guangqiao [3 ,4 ]
Chen, Man [5 ]
Zhang, Sai [3 ,4 ]
Zhou, Yufu [2 ]
Shi, Bo [3 ,4 ]
Zhang, Xiaochun [1 ,5 ]
机构
[1] Yangzhou Univ, Sch Med, Yangzhou, Jiangsu, Peoples R China
[2] Bengbu Med Coll, Affiliated Hosp 1, Dept Radiat Oncol, Bengbu, Anhui, Peoples R China
[3] Bengbu Med Coll, Sch Med Imaging, Bengbu, Anhui, Peoples R China
[4] Bengbu Med Coll, Anhui Key Lab Computat Med & Intelligent Hlth, Bengbu, Anhui, Peoples R China
[5] Yangzhou Hosp Tradit Chinese Med, Dept Oncol, Yangzhou, Jiangsu, Peoples R China
关键词
heart rate variability; nonlinear methods; heartbeat complexity; recurrence quantification analysis; advanced non-small cell lung cancer; prognosis; VAGAL NERVE ACTIVITY; RATE-VARIABILITY; BREAST-CANCER; APPROXIMATE ENTROPY; OUTCOMES; TIME; QUANTIFICATION; INFLAMMATION; DYNAMICS;
D O I
10.3389/fnins.2023.1113225
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
BackgroundPrevious studies have shown that the predictive value of traditional linear (time domain and frequency domain) heart rate variability (HRV) for the survival of patients with advanced non-small cell lung cancer (NSCLC) is controversial. Nonlinear methods, based on the concept of complexity, have been used to evaluate HRV, providing a new means to reveal the physiological and pathological changes in HRV. This study aimed to assess the association between heartbeat complexity and overall survival in patients with advanced NSCLC. MethodsThis study included 78 patients with advanced NSCLC (mean age: 62.0 +/- 9.3 years). A 5-min resting electrocardiogram of advanced NSCLC patients was collected to analyze the following HRV parameters: time domain indicators, i.e., standard deviation of the normal-normal intervals (SDNN) and root mean square of successive interval differences (RMSSD); frequency domain indicators, i.e., total power (TP), low frequency power (LF), high frequency power (HF), and the ratio of LF to HF (LF/HF); nonlinear HRV indicators characterizing heartbeat complexity, i.e., approximate entropy (ApEn), sample entropy (SampEn), and recurrence quantification analysis (RQA) indexes: mean diagonal line length (Lmean), maximal diagonal line length (Lmax), recurrence rate (REC), determinism (DET), and shannon entropy (ShanEn). ResultsUnivariate analysis revealed that the linear frequency domain parameter HF and nonlinear RQA parameters Lmax, REC, and DET were significantly correlated with the survival of advanced NSCLC patients (all p < 0.05). After adjusting for confounders in the multivariate analysis, HF, REC, and DET were found to be independent prognostic factors for the survival of patients with advanced NSCLC (all p < 0.05). ConclusionThere was an independent association between heartbeat complexity and survival in advanced NSCLC patients. The nonlinear analysis method based on RQA may provide valuable additional information for the prognostic stratification of patients with advanced NSCLC and may supplement the traditional time domain and frequency domain analysis methods.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Survival predictors in advanced non-small cell lung cancer
    Hespanhol, V
    Queiroga, H
    Magalhaes, A
    Santos, AR
    Coelho, M
    Marques, A
    [J]. LUNG CANCER, 1995, 13 (03) : 253 - 267
  • [2] The association of prechemotherapy neutorphil-lymphocyte ratio with survival in advanced non-small cell lung cancer patients
    Mangle, Ankit
    Thekkekara, Romy
    Yadav, Udit
    Mohajer, Roozbeh
    Lad, Thomas E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
    Zhao, Dan
    Mambetsariev, Isa
    Li, Haiqing
    Chen, Chen
    Fricke, Jeremy
    Fann, Patricia
    Kulkarni, Prakash
    Xing, Yan
    Lee, Peter
    Bild, Andrea
    Massarelli, Erminia
    Koczywas, Marianna
    Reckamp, Karen
    Salgia, Ravi
    [J]. CANCER RESEARCH, 2020, 80 (16)
  • [4] Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy
    Sehgal, Kartik
    Gill, Ritu R.
    Widick, Page
    Bindal, Poorva
    McDonald, Danielle C.
    Shea, Meghan
    Rangachari, Deepa
    Costa, Daniel B.
    [J]. JAMA NETWORK OPEN, 2021, 4 (02)
  • [5] Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors
    Zhao, Dan
    Mambetsariev, Isa
    Li, Haiqing
    Chen, Chen
    Fricke, Jeremy
    Fann, Patricia
    Kulkarni, Prakash
    Xing, Yan
    Lee, Peter P.
    Bild, Andrea
    Massarelli, Erminia
    Koczywas, Marianna
    Reckamp, Karen
    Salgia, Ravi
    [J]. LUNG CANCER, 2020, 146 : 174 - 181
  • [6] Joint Modeling of Stress and Survival in Patients with Advanced Non-Small Cell Lung Cancer
    Arrato, N.
    Brock, G.
    Mcelroy, J.
    Andersen, B.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S119 - S120
  • [7] Comorbidity and survival for patients with advanced-stage non-small cell lung cancer
    Chrischilles, Elizabeth A.
    Abu Hejleh, Taher
    Carter, Knute D.
    Pendergast, Jane F.
    Halfdanarson, Thorvardur Ragnar
    Fletcher, Robert H.
    Wallace, Robert B.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Survival data in elderly patients with locally advanced non-small cell lung cancer
    Domingues, Pedro Masson
    Zylberberg, Ricardo
    de Castro, Thalita da Matta
    Baldotto, Clarissa Serodio
    de Lima Araujo, Luiz Henrique
    [J]. MEDICAL ONCOLOGY, 2013, 30 (01)
  • [9] Prognostic Factors Affecting Survival in Advanced Non-Small Cell Lung Cancer Patients
    Songur, Necla
    Kuru, Bekir
    Ok, Ugur
    [J]. TURKISH THORACIC JOURNAL, 2005, 6 (02) : 91 - 97
  • [10] Survival data in elderly patients with locally advanced non-small cell lung cancer
    Pedro Masson Domingues
    Ricardo Zylberberg
    Thalita da Matta de Castro
    Clarissa Seródio Baldotto
    Luiz Henrique de Lima Araujo
    [J]. Medical Oncology, 2013, 30